Bioavailability of intranasal scopolamine in normal subjects

Journal of Pharmaceutical Sciences

Volumn 85, Issue 8, 1996, Pages 899-902

  Putcha, Lakshmi ^a   Tietze, Karen J ^b   Bourne, David W A ^c   Parise, Cecelia M ^a   Hunter, Robert P ^a   Cintrón, Nitza M ^a  

^a NASA JOHNSON SPACE CENTER   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SCOPOLAMINE BROMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOTION SICKNESS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; REVERSED PHASE LIQUID CHROMATOGRAPHY; SALIVATION;

EID: 0029761048     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js950327b     Document Type: Article

References (22)

1. Chien, Y. W.; Chang, S.-F. Intranasal drug delivery for systematic medications. In Critical Reviews in Therapeutic Drug Carrier Systems; Bruck, S. D., Ed.; CRC Press Inc.: Boca Raton, FL, 1987; pp 67-194.
2. Fink, G.; Gennser, G.; Liedholm, P.; Thorell, J.; Mulder, J. Comparison of plasma levels of luteinizing hormone releasing hormone in men after intravenous or intranasal administration. J. Endocrinol. 1974, 63, 351-360.
3. Yokosuka, T.; Omori, Y.; Hirata, Y.; Hirai, S. Nasal and sublingual administration of insulin in man. J. Jpn. Diabetes Soc. 1977, 20, 146-152.
4. Hussain, A. A.; Foster, T.; Hirai, S.; Kashihawa, T.; Batenhorst, R.; Jones, M. Nasal absorption of propranolol in humans. J. Pharm. Sci. 1980, 69, 1240.
5. Javaid, J. I.; Musa, M. N.; Fischman, M.; Schuster, C. R.; Davis, J. M. Kinetics of cocaine in humans after intravenous and intranasal administration. Biopharm. Drug Dispos. 1983, 4, 9-18.
6. Chinn, H. I.; Hyde, R. W.; Milch, L. J. Prevention and treatment of motion sickness by intranasal medication. Proc. Soc. Exp. Biol. Med. 1955, 90, 666-669.
7. Wood, C. D.; Graybiel, A. Evaluation of 16 anti-motion sickness drugs under controlled laboratory conditions. Aerospace Med. 1968, 39, 131-134.
8. Graybiel, A. Prevention and treatment of space sickness in shuttle-orbiter missions. Aviat., Space Environ. Med. 1979, 50, 171-176.
9. Tonndorf, J.; Chinn, H. I.; Lett, J. E. Absorption from nasal mucous membrane: Systemic effect of hyoscine following intranasal administration. Ann. Otol., Rhinol., Laryngol. 1953, 62, 630-641.
10. Hyde, R. W.; Tonndorf, J.; Chinn, H. E. Absorption from the nasal mucous membrane. Ann. Otol., Rhinol., Laryngol. 1953, 62, 957-968.
11. Putcha, L.; Cintrón, N. M.; Tsui, J.; Vanderploeg, J. M.; Kramer, W. G. Pharmacokinetics and oral bioavailability of scopolamine in normal subjects. Pharm. Res. 1989, 6, 481-485.
12. Shaw, J.; Urquhart, J. Programmed systemic drug delivery by the transdermal route. Trends Pharmacol. Sci. 1980, 2, 208-211.
13. Cintrón, N. M.; Chen, Y. A sensitive radioreceptor assay for determining scopolamine concentrations in plasma and urine. J. Pharm. Sci. 1987, 76, 328-332.
14. Gibaldi, M.; Perrier, D. Pharmacokinetics, 2nd ed.; Marcel Dekker: New York, 1982.
15. Hussain, A. A.; Bawarshi-Nassar, R.; Huang, C. H. Physicochemical considerations in intranasal drug administration. In Transnasal Systemic Medications; Chien, Y. W., Ed.; Elsevier Science Publications: Amsterdam, 1985.
16. Golding, J. F.; Gosden, E.; Gerrell, J. Scopolamine blood levels following buccal vs. ingested tablets. Aviat., Space Environ. Med. 1991, 62, 521-526.
17. McCauley, M. E.; Royal, J. W.; Shaw, J. E.; Schmitt, L. G. Effect of transdermally administered scopolamine in preventing motion sickness. Aviat., Space Environ. Med. 1979, 50 (11), 1108-1111.
18. Graybiel, A.; Cramer, D. B.; Wood, C. D. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration. Aviat., Space Environ. Med. 1982, 53 (8), 770-772.
19. Homick, J. L.; Kohl, R. L.; Reschke, M. F.; Degioanni, J.; Cintrón-Trevino, N. M. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy. Aviat., Space Environ. Med. 1983, 54 (11), 994-1000.
20. Price, N. M.; Schmitt, L. G.; McGuire, J.; Shaw, J. E.; Trobough, G. Transdermal scopolamine in the prevention of motion sickness at sea. Clin. Pharmacol. Ther. 1981, 29, 414-419.
21. van Marion, W. F.; Bongaerts, M. C.; Christiaanse, J. C.; Hofkamp, H. G.; van Ouwerkerk, W. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas. Clin. Pharmacol. Ther. 1985, 38 (3), 301-305.
22. Grundhoffer, B.; Gibaldi, M. Biopharmaceutic factors that influence effects of anticholinergic drugs: comparison of propantheline, hexocyclium, and isopropamide. J. Pharm. Sci. 1977, 66, 1433-1435.